About the Event
Camallergy has developed an innovative treatment for the more than 6 million people in the U.S. and Europe who live with peanut allergies. Their oral immunotherapy provides protection to patients within 14 weeks of treatment. It’s a game-changing treatment that:
- Achieved best-in-class results in over 300 children treated in an early access clinic and phase 2 trial
- Is unanimously preferred by allergists over the current treatment option
- Enhanced by a novel medical device to dramatically improve patient and physician experience
- Is a platform technology that extends to other food allergies
Join our webinar with Camallergy CEO, Sherden Timmins to hear more about how the company plans to have this cutting-edge treatment ready for Phase 3 Clinical Trials in 2023 and commercial launch in 2026.